Bristol-Myers Squibb: Small Cell Lung Carcinoma trials

The registry lists 20 Small Cell Lung Carcinoma studies with Bristol-Myers Squibb as lead sponsor. 2 are open to participants now and 6 have results posted.

Phase 1 8Phase 2 7Phase 3 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerRecruitingNCT07325136Phase 1/2
• A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).RecruitingNCT06646276Phase 3
• A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerCompletedNCT04702880Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyCompletedNCT02538666Phase 3Results posted
• Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerCompletedNCT02481830Phase 3Results posted
• BMS-986012 in Relapsed/Refractory SCLCCompletedNCT02247349Phase 1/2Results posted
• Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneCompletedNCT01450761Phase 3Results posted
• Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)CompletedNCT00527735Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung CancerCompletedNCT06799286Phase 1
• A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung CancerCompletedNCT03850067Phase 1
• Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung CancerCompletedNCT03505515
• Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)CompletedNCT03425825
• Study of BMS-986012 in Subjects With Small Cell Lung CanerCompletedNCT02949895Phase 1
• Trial of BMS-986012 in Combination With Platinum and EtoposideCompletedNCT02815592Phase 1
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung CancerCompletedNCT00927875Phase 1
• AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line ChemotherapyCompletedNCT00547651Phase 3
• Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung CancerCompletedNCT00388960Phase 2
• Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior TherapyCompletedNCT00375193Phase 2
• Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.CompletedNCT00319969Phase 2